- Current report filing (8-K)
June 11 2012 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): June 5, 2012
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
The 2012 Annual Meeting of Stockholders (the Annual Meeting) of Sunesis Pharmaceuticals, Inc. was held on June 5, 2012. Proxies for the Annual Meeting were solicited by our Board of
Directors (the Board) pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Boards solicitation. There were 46,924,232 shares of common stock entitled
to vote at the Annual Meeting. A total of 40,270,997 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the meeting were as follows:
Proposal No. 1
Edward Hurwitz, Helen S. Kim and Dayton Misfeldt were elected as directors to hold office until the 2015 Annual Meeting of Stockholders by
the following vote:
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Edward Hurwitz
|
|
24,948,008
|
|
3,140,022
|
|
12,182,967
|
Helen S. Kim
|
|
27,732,741
|
|
355,289
|
|
12,182,967
|
Dayton Misfeldt
|
|
25,390,045
|
|
2,697,985
|
|
12,182,967
|
In addition to the directors elected above, James W. Young, Ph.D., Steven B. Ketchum, Ph.D. and Homer L.
Pearce, Ph.D. will continue to serve as directors until the 2013 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or removal. Matthew K. Fust, David C. Stump, M.D.
and Daniel N. Swisher, Jr. will continue to serve as directors until the 2014 Annual Meeting of Stockholders and until their successors are elected and have qualified, or until their earlier death, resignation or removal.
Proposal No. 2
The
selection by the Audit Committee of the Board of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2012 was ratified by the following vote:
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
40,156,762
|
|
69,614
|
|
44,621
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
|
|
Dated: June 11, 2012
|
|
|
|
|
By:
|
|
/s/ Eric H. Bjerkholt
|
|
|
|
|
Eric H. Bjerkholt
|
|
|
|
|
Executive Vice President, Corporate Development and Financing, Chief Financial Officer and Corporate Secretary
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024